Search research articles
Contact Us
Filters
Showing results (41-50 of 62) with videos related to
Page
of 7
Sort By:
Blood Advances
|
February 18, 2026
Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM
Manali Kamdar, Scott R Solomon, Jon E Arnason, et al.
Cancer Research Communications
|
April 30, 2024
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
Alexandria P Eiken, Audrey L Smith, Sydney A Skupa, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 1, 2021
Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
N Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
JCI Insight
|
May 22, 2024
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
Audrey L Smith, Sydney A Skupa, Alexandria P Eiken, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 19, 2021
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
N Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
Lancet (London, England)
|
September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, et al.
Blood Advances
|
January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology
|
March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Blood
|
December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 62) with videos related to
Sort By:
Page
of 7
Blood Advances
|
February 18, 2026
Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM
Manali Kamdar, Scott R Solomon, Jon E Arnason, et al.
Cancer Research Communications
|
April 30, 2024
Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects
Alexandria P Eiken, Audrey L Smith, Sydney A Skupa, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 1, 2021
Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
N Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
JCI Insight
|
May 22, 2024
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia
Audrey L Smith, Sydney A Skupa, Alexandria P Eiken, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 19, 2021
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience
N Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
Lancet (London, England)
|
September 5, 2020
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 19, 2023
PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, et al.
Blood Advances
|
January 30, 2025
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, et al.
American Journal of Hematology
|
March 20, 2024
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy
Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, et al.
Blood
|
December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Page
of 7